Tuberculosis was never "cured" as a single moment, but became treatable starting in 1943

There is no year when tuberculosis was cured. Instead, TB shifted from a death sentence to a manageable infection over several decades, beginning with the discovery of the first effective drug in 1943. Before that, people diagnosed with TB faced a long decline—some recovered on their own, many did not. After streptomycin arrived, and especially after combination therapy became standard in the 1950s, TB stopped being fatal for most people who could access treatment.

Today, TB is curable in the vast majority of cases, but it is not gone, and it still kills people who do not receive the right drugs. The difference between a cure and a death sentence now depends almost entirely on whether someone has access to a specific set of antibiotics and the support to take them for the full course—usually four to six months. In wealthy countries, this access is nearly universal. In parts of the world with weaker health systems, TB remains a leading cause of death.

Key Takeaways

  • Streptomycin, discovered in 1943, was the first drug that could kill the tuberculosis bacterium, but it worked alone only about half the time because bacteria developed resistance within weeks.
  • Combination therapy—using two, three, or four drugs together—became the standard approach in the 1950s and made TB curable in more than 95 percent of cases.
  • TB declined sharply in wealthy countries after antibiotics arrived, but resurged in the 1980s and 1990s due to drug-resistant strains and HIV weakening immune systems.
  • Tuberculosis remains curable today with a six-month course of four specific antibiotics, but requires completing the full treatment even after symptoms disappear.

What changed when streptomycin arrived in 1943

Before streptomycin, TB treatment meant rest, fresh air, and hoping the body's immune system could contain the infection. Sanatoriums—hospitals dedicated to TB care—housed thousands of patients in the belief that isolation and climate would help. Some people did recover this way, but many died, and there was no way to predict who would survive. Families often sent relatives to sanatoriums knowing they might never return.

Streptomycin was the first antibiotic shown to kill Mycobacterium tuberculosis, the bacterium that causes TB. When it was tested on patients in 1944 and 1945, the results were dramatic: people who had been bedridden began to improve within weeks. But streptomycin alone had a serious problem—the bacterium developed resistance to it within weeks or months. Patients would improve, then relapse as the drug stopped working. TB was no longer automatically fatal, but it was not yet curable.

How combination therapy made TB curable in the 1950s

The breakthrough came when researchers realized that using multiple drugs at once could prevent resistance. If a bacterium developed resistance to one drug, the other drugs could still kill it. By the mid-1950s, doctors were using combinations of three or four drugs—typically streptomycin, isoniazid, and para-aminosalicylic acid (PAS)—given together for 18 to 24 months.

This approach worked. Cure rates climbed above 90 percent, and then higher. TB stopped being the leading cause of death in developed countries. Sanatoriums closed. The disease became something that could be reliably treated, not something that defined the end of a person's life. By the 1960s and 1970s, TB had become so rare in wealthy nations that many doctors never saw a case in their entire career.

Why TB declined so rapidly after the 1950s

The speed of TB's decline in wealthy countries was striking. In the United States, TB deaths fell from about 200 per 100,000 people in 1900 to fewer than 5 per 100,000 by 1960. This happened because antibiotics were widely available, because public health programs tracked cases and ensured people completed treatment, and because living conditions improved—better nutrition, less crowding, and better ventilation all made TB less likely to spread.

But the decline was not universal. In countries with less access to antibiotics, less robust public health systems, or both, TB remained common. This gap between wealthy and poor nations has persisted for 70 years. A person with TB in Norway today has a very different outcome than a person with TB in parts of sub-Saharan Africa, not because the disease is different, but because access to the right drugs and the support to complete treatment is different.

The resurgence of TB in the 1980s and 1990s

In the 1980s, TB cases began rising again in the United States and other wealthy countries. Two things drove this: the HIV epidemic, which weakened immune systems and made TB much more likely to develop in infected people, and the emergence of drug-resistant strains. Some patients did not complete their full course of antibiotics—either because they felt better and stopped taking them, or because they could not access the drugs consistently. Incomplete treatment left behind bacteria that had survived the drugs, and these resistant bacteria spread to others.

Multidrug-resistant TB (MDR-TB), which resists at least isoniazid and rifampicin (the two most powerful first-line drugs), emerged as a serious problem. Some strains were resistant to even more drugs. These cases required longer treatment with more toxic drugs, and cure rates dropped. The idea that TB was a solved problem—that it belonged to history—turned out to be premature.

How TB is treated and cured today

Standard TB treatment today uses four drugs for the first two months, then two drugs for the remaining four months—a total of six months. The drugs are isoniazid, rifampicin, pyrazinamide, and ethambutol. This regimen cures more than 95 percent of people who complete it, even though symptoms usually disappear after two to four weeks. The reason people must continue taking drugs after they feel better is that some bacteria survive longer than others; stopping early leaves behind resistant bacteria that can multiply.

For drug-resistant TB, treatment is longer and harder. MDR-TB typically requires 20 months of treatment with five or more drugs, some of which cause serious side effects. Extensively drug-resistant TB (XDR-TB) requires even longer treatment with newer drugs like bedaquiline and linezolid. These newer drugs are expensive and not available everywhere, which is why drug-resistant TB remains a major public health problem in countries with limited resources.

Why TB still kills people despite being curable

TB kills roughly 1.3 million people each year worldwide, making it one of the top ten causes of death globally. Most of these deaths are preventable. People die from TB because they do not have access to antibiotics, because they do not know they have TB and do not seek care, because they cannot afford the drugs, or because they stop taking them before the course is complete.

In wealthy countries, TB deaths are rare because diagnosis is straightforward, drugs are available, and public health systems track patients to make sure they finish treatment. In countries with weak health systems, TB spreads more easily, diagnosis takes longer, and people may not be able to afford or access the full course of drugs. This is not because the disease is different or because the cure does not work—it is because the conditions that allow cure to happen are not in place.

Frequently Asked Questions

Is tuberculosis still contagious if someone is taking antibiotics?

Yes, but much less so. People with active TB are most contagious before treatment starts. After about two weeks of the right antibiotics, most people stop shedding bacteria into the air and become non-contagious. This is why people with TB are usually isolated in the hospital for the first two weeks of treatment, then can go home.

Can you get TB again after you have been cured?

Yes, but it is uncommon. If you complete a full course of TB antibiotics, you are cured—the bacteria are dead. You can catch TB again if you are exposed to someone with active TB, just as you could catch it the first time. People with HIV or other conditions that weaken immunity are at higher risk of developing TB again after a previous infection.

Why does TB treatment take so long?

The tuberculosis bacterium grows slowly and has a thick, waxy coat that makes it hard for antibiotics to reach. Some bacteria are dormant—not actively growing—and dormant bacteria are harder to kill. A full six months of treatment is needed to kill all the bacteria, including the slow-growing and dormant ones. Stopping early leaves behind bacteria that can multiply and cause relapse.

What is latent tuberculosis, and can it turn into active TB?

Latent TB means you have been infected with the bacterium but your immune system has contained it—you have no symptoms and cannot spread it to others. About 5 to 10 percent of people with latent TB will develop active TB at some point in their life, usually within the first two years after infection. People with HIV, diabetes, or other conditions that weaken immunity are at much higher risk.

Are there any new TB drugs in development?

Yes. Bedaquiline, approved in 2012, and linezolid, approved for TB in 2019, are newer drugs that work against drug-resistant strains. Researchers are also testing shorter regimens for drug-resistant TB and new combinations that might reduce treatment time. However, these drugs are expensive and not yet widely available in low-income countries where TB is most common.